Alembic Pharma gets USFDA nod for seizures treatment drug

Alembic Pharma has received final approval from the US health regulator for Lacosamide tablets, used for treatment of partial-onset seizures, in the American market.

"The company has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Lacosamide tablets, 50 mg, 100 mg, 150 mg and 200 mg," Alembic Pharmaceuticals said in a BSE filing.

Read more from our special coverage on "ALEMBIC PHARMA"

• Alembic Pharmas Panelav unit may get minor USFDA observations

The product is generic version of drug firm UCB Inc's Vimpat tablets in the same strengths, it added.

The launch of this product will be based on the outcome of the ongoing litigation in the US District Court with UCB, Alembic said.

The company was one of the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification, it added.

The tablets are indicated as adjunctive therapy in patients with partial onset seizures, Alembic Pharma said.

"The company currently has 47 ANDA approvals (43 final approvals and 4 tentative approvals from the USFDA," it added.

Alembic stock was trading 0.17% down at Rs 601.90 in the afternoon trade on BSE.